Premium
5‐HT 6 antagonists as potential treatment for cognitive dysfunction
Author(s) -
Liu Kevin G.,
Robichaud Albert J.
Publication year - 2009
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20293
Subject(s) - neuroscience , glutamatergic , pharmacology , schizophrenia (object oriented programming) , cognition , antagonism , antagonist , tricyclic , cholinergic , psychology , receptor , medicine , glutamate receptor , psychiatry
Among the potential therapeutic targets for the development of cognitive enhancers for AD and schizophrenia, the 5‐HT 6 receptor is of especial interest based on its localization, pharmacology, and recent behavioral data showing that 5‐HT 6 receptor blockade improves cognition in a number of rodent behavioral models. It is localized almost exclusively in the CNS, in areas important for learning and memory, while atypical antipsychotics and tricyclic antidepressants bind with high affinity to this target. 5‐HT 6 receptor antagonism enhances neurotransmission at cholinergic and glutamatergic neurons, as well as in other pathways. 5‐HT 6 antagonist medicinal chemistry and potential therapeutic applications for treatment of cognitive dysfunction is broadly reviewed. Drug Dev Res 70, 2009 © 2009 Wiley‐Liss, Inc.